Compare BZH & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZH | GOSS |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.0M | 615.7M |
| IPO Year | 1995 | 2018 |
| Metric | BZH | GOSS |
|---|---|---|
| Price | $24.06 | $0.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $32.00 | $5.90 |
| AVG Volume (30 Days) | 513.4K | ★ 23.8M |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,087,739,000.00 | $114,701,000.00 |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $12.21 | $6.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.37 | $0.33 |
| 52 Week High | $28.33 | $3.87 |
| Indicator | BZH | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 17.76 |
| Support Level | $20.08 | N/A |
| Resistance Level | $24.22 | $1.31 |
| Average True Range (ATR) | 0.89 | 0.12 |
| MACD | -0.43 | -0.14 |
| Stochastic Oscillator | 18.81 | 6.58 |
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.